Rifamycin SV MMX®
Rifamycin SV MMX® is a pharmaceutical product employing Rifamycin SV engineered with the MMX® technology. Rifamycin SV is a broad spectrum, semi-synthetic, orally non-absorbable antibiotic which can be used for the treatment of bacterial infections of the colon such as traveler’s diarrhea, infectious colitis, Clostidium difficile associated disease, diverticulitis and also as supportive treatment of Inflammatory Bowel Diseases and Hepatic Encephalopathy. The application of MMX® technology to Rifamycin SV allows the antibiotic to be delivered directly into the colon, avoiding unwanted effects on the beneficial bacterial flora living in the upper portions of the gastro-intestinal tract. The specific dissolution profile of Rifamycin SV MMX® tablets is thought to increase the colonic disposition of the antibiotic so that an optimized intestinal concentration is achieved thus abating its systemic absorption in the small intestine.
Phase III clinical trials in traveler's diarrhea have been completed in America and are currently ongoing in the EU.
It is intended that Rifamycin SV MMX® will initially be indicated for the treatment of patients with travelers' diarrhea. A daily dose of 800 mg, usually consisting of four tablets at 200 mg a day, is recommended.
Rifamycin SV MMX® is licensed to Dr. Falk Pharma for Europe.
Cosmo's patent expires in the year 2025.